Tumor Control and Normal Tissue Complications in High-dose-rate Brachytherapy for Cervical Cancer Patients Using Ir-192 Radioactive Source.

Gurpreet Kaur, Pardeep Garg, Vinod Kumar Dangwal, Baltej Singh, Garima Gaur, Romikant Grover, Simrandeep Singh, Rachana Sharma
Author Information
  1. Gurpreet Kaur: Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
  2. Pardeep Garg: Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
  3. Vinod Kumar Dangwal: Department of Radiation Oncology, Government Medical College, Patiala, Punjab, India.
  4. Baltej Singh: Department of Community Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
  5. Garima Gaur: Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
  6. Romikant Grover: Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
  7. Simrandeep Singh: Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
  8. Rachana Sharma: Department of Sociology, Guru Nanak Dev University, Amritsar, Punjab, India.

Abstract

Introduction: The purpose of the study was to calculate, tumor control probability (TCP) and normal tissue complication probability (NTCP) in cervical cancer patients and to clinically correlate the outcomes with a follow-up period of 24 months.
Materials and Methods: One hundred and fifty patients were included in the present study who received 46 Gy/23 fractions/4½ weeks of external beam radiotherapy with concurrent cisplatin chemotherapy, followed by intracavitary brachytherapy of 3 different fractionations regimens, i.e., 9.5 Gy per fraction of two fractions (50 patients in Arm1), 7.5 Gy per fraction of three fractions (50 patients in Arm2), and 6.0 Gy per fraction of four fractions (50 patients in Arm3).
Results: The median TCP value for Arm1, Arm2, and Arm3 was 99.6%, 94%, and 98.1%, respectively, ( < 0.01). The median NTC value for bladder in Arm1, Arm2, and Arm3 was 0.17%, 0.04%, and 0.07%, respectively, ( = 0.05). The median NTC value for rectum in Arm1, Arm2, and Arm3 was 4.73%, 4.35%, and 3.17%, respectively, ( = 0.052). The overall survival (OS) of 90%, 86%, and 84% was found for Arm1, Arm2, and Arm3, respectively, at 24 months of follow-up.
Conclusion: TCP, NTCP, and OS rates were found higher in Arm1 as compared to the other two arms. The complications found in all arms were less, low grade, and manageable. Hence, Arm1, i.e., 9.5 Gy per fraction of two fractions can be concluded as the optimum fractionation regime in terms of radiobiological parameters as well as overall patient comfort.

Keywords

References

  1. Brachytherapy. 2012 Jan-Feb;11(1):47-52 [PMID: 22265437]
  2. Phys Med. 2024 Feb;118:103294 [PMID: 38199178]
  3. J Contemp Brachytherapy. 2022 Jun;14(3):253-259 [PMID: 36199997]
  4. Radiother Oncol. 2005 Mar;74(3):235-45 [PMID: 15763303]
  5. Lancet Glob Health. 2020 Feb;8(2):e191-e203 [PMID: 31812369]
  6. Radiother Oncol. 2021 Jul;160:273-284 [PMID: 34019918]
  7. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):356-62 [PMID: 20385450]
  8. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46 [PMID: 2032884]
  9. Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):135-45 [PMID: 8416870]
  10. JCO Glob Oncol. 2020 Jul;6:1063-1075 [PMID: 32673076]
  11. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [PMID: 7713792]
  12. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):56-63 [PMID: 19289267]
  13. J Contemp Brachytherapy. 2019 Aug;11(4):293-306 [PMID: 31523229]
  14. Brachytherapy. 2012 Jan-Feb;11(1):33-46 [PMID: 22265436]
  15. Int J Med Sci. 2008 Feb 19;5(1):41-9 [PMID: 18311328]
  16. Adv Bioinformatics. 2014;2014:376207 [PMID: 24665263]

Word Cloud

Created with Highcharts 10.0.0Arm10patientsArm2Arm3probabilityGyperfractionfractionsrespectivelyTCP5two50medianvaluefoundstudytumorcontrolnormaltissuecomplicationNTCPfollow-up24monthsradiotherapy3ie9NTC17%=4overallOSarmsBrachytherapyIntroduction:purposecalculatecervicalcancerclinicallycorrelateoutcomesperiodMaterialsMethods:Onehundredfiftyincludedpresentreceived46Gy/23fractions/4½weeksexternalbeamconcurrentcisplatinchemotherapyfollowedintracavitarybrachytherapydifferentfractionationsregimens7three6fourResults:996%94%981%<01bladder04%07%05rectum73%35%052survival90%86%84%Conclusion:rateshighercomparedcomplicationslesslowgrademanageableHencecanconcludedoptimumfractionationregimetermsradiobiologicalparameterswellpatientcomfortTumorControlNormalTissueComplicationsHigh-dose-rateCervicalCancerPatientsUsingIr-192RadioactiveSourcecarcinomauterinecervix

Similar Articles

Cited By